hepatocytes. In this study, to provide insight into the preventive effects of d-allose, a rare sugar, on the onset of NASH, we designed animal experiments using male STAM mice treated with streptozotocin and fed a high-fat diet (HFD). Experiments were initiated when the mice reached 5 weeks of age and lasted 3 weeks. After the 3-week protocol, mice fed the HFD containing d-allose exhibited significantly decreased serum alanine aminotransferase levels, hepatic lipid accumulation and inflammation, and improved nonalcoholic fatty liver disease activity score compared to mice fed HFD without d-allose ( p < 0.05). Further, hepatic mRNA expression of sterol regulatory element binding protein-1 (Srebp-1) and monocyte chemotactic protein-1 (Mcp-1) was lower in mice fed d-allose.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is an increasingly common hepatic phenotype of metabolic syndrome not caused by chronic alcohol consumption and is characterized by lipid accumulation in hepatocytes (Williams et al., 2011) . Nonalcoholic steatohepatitis (NASH), a type of NAFLD, is a significant risk factor for the development of cirrhosis and hepatocellular carcinoma (Feldstein et al., 2009; Cohen et al., 2011) . The two-hit theory (Day and James, 1998) and multiple parallel hits hypothesis (Tilg et al., 2010) have been used to explain the progression of simple steatosis to NASH via lipid accumulation, inflammation, and oxidative stress in the liver, although the exact mechanisms
have not yet been elucidated.
In the alternative medicinal food sciences, recent reports have claimed that excessive sugar intake (e.g., d-fructose and highfructose corn syrup) is a high risk factor in the progression of NAFLD/NASH (Abdelmalek et al., 2010; Nseir et al., 2010) .
Meanwhile, the physiological effects of rare sugars, such as d-allose, have recently attracted attention as physiological mediators of such diseases. d-Allose is a d-glucose epimer at C3 and can be industrially obtained from d-psicose by using rhamnose isomerase (Menavuvu et al., 2006) . For example, d-allose has been shown to protect against inflammatory and oxidative ischemia/ reperfusion (I/R) injury in liver, retinal, and cerebral injuries in rodent models (Hossain et al., 2003; Hirooka et al., 2006; Gao et al., 2013) . Previous studies have revealed the physiological benefits of d-allose, including anti-inflammatory effects resulting from reduced myeloperoxidase (MPO) activity and reduced adherent neutrophils in organs (Hossain et al., 2003) , and anti-oxidant effects resulting from reduced production of H 2 O 2 or O 2 _ (Hirooka et al., 2006; Mizote et al., 2011) . Intake of anti-inflammatory or anti-oxidant compounds can be used to prevent the development of NAFLD/NASH (Park et al., 2011; Ni et al., 2015) . Thus, d-allose may have the potential to contribute to the prevention of NAFLD/ NASH, as well as I/R injury, caused by excess inflammation and/or oxidative stress in the liver.
In this study, we hypothesized that dietary d-allose could prevent NAFLD/NASH. STAM mice, i.e., C57BL/6J mice treated with streptozotocin (STZ) and fed a high-fat diet (HFD), were used as a rodent model of NASH to investigate the preventive effects of d-allose against NASH. Our results indicate that d-allose may alleviate or prevent NASH through reduced fat accumulation and inflammation in the liver.
Materials and Methods

Animals and experimental design, and sample preparation
STAM mice were used to model NASH and were obtained according to the method described by Fujii et al. (2013) . Pathogenfree, 14-day pregnant female C57BL/6J mice were purchased from Charles River Laboratories (Tokyo, Japan). To induce NASH, STAM mice were primarily obtained by treating C57BL/6J mice with a single subcutaneous injection of 200 µg STZ (Sigma-Aldrich, St. Louis, MO, USA) 2 days after birth. At 4 weeks of age, the mice were fed a HFD (HFD32; CLEA Japan, Tokyo, Japan) ad libitum for 1 week (the experimental scheme is shown in Fig. 1 ). At 5 weeks of age, the STAM mice with hepatic steatosis were randomly divided into two groups, the STAM group (HFDfeeding) and the DA-STAM group (HFD containing ca. 2% (precisely 1.96%) d-allose-feeding), and housed for 3 weeks. The diet compositions are shown in Table 1 . d-Allose was provided by the Kagawa University Rare Sugar Research Center (Kagawa, Japan). In this study, a 2% d-allose-diet was used for the STAM mice experiment, based on a previous report demonstrating that this d-allose concentration has potential inhibitory effects on other liver diseases (hepatocarcinogenesis), whereas a lower dose (0.01 _ 1.0%) has no effect on the development of liver diseases (Yokohira et al., 2008) . C57BL/6J mice without STZ treatment and fed an AIN93G diet (Oriental Yeast, Tokyo, Japan) were used as a control group. All mice were housed in colony cages with a 12hour light/dark cycle, controlled temperature (24 ± 1℃), and were given free access to food and water. At 8 weeks after birth, the mice were fasted overnight, then anesthetized with pentobarbital sodium (64.8 mg/g, Kyoritsu Seiyaku, Tokyo, Japan) and
sacrificed. Blood and liver samples were collected; serum samples were stored at _ 30℃ until use, and liver samples were immediately Fig. 1 . The animal experimental scheme. Protocols were composed of three animal groups, i.e., control (C57BL6J fed AIN93G), STAM (STAM mice fed a HFD) and DA-STAM (STAM mice fed a HFD containing 2% d-allose) groups. Experiments started at 5 weeks from birth and lasted for 3 weeks. STAM mice were primarily generated from C57BL/6J mice by a single subcutaneous injection of STZ on day 2 after birth, and at 4 weeks of age, they were fed with a HFD ad libitum. During breast-feeding, maternal mice were fed a normal diet (AIN93G). DA, d-allose; STZ, streptozotocin; ND, normal diet (AIN93G); HFD, high-fat diet (HFD 32) washed in ice-cold Ringer's solution ( Analysis of lipid accumulation in the liver Liver samples were homogenized in ice-cold phosphate buffered saline (PBS). Liver lipids were extracted using Folch's method (Folch et al., 1957) (Abramoff et al., 2004; Schneider et al., 2012) .
Hepatic pathological diagnosis Paraffin-embedded, formalinfixed liver sections were stained with hematoxylin and eosin (H&E), and representative images were obtained using a Shimadzu BA210E microscope at 200× magnification (Shimadzu BA210E).
The magnitude of the liver injury was evaluated using NAFLD activity score (NAS), whereby the sum of the scores from three equal weighted features of steatosis (0 _ 3), lobular inflammation (0 _ 3), and hepatocellular ballooning (0 _ 2) was calculated (Kleiner et al., 2005) . According to the criteria outlined by Hjelkrem et al. (2011) , the NAS of 4 or more, 3, and 2 or less were defined as NASH, borderline NASH, and non-NASH, respectively. Table 2 .
Statistical analysis Results are expressed as the mean ± standard error of the mean (SEM). Statistical analysis was performed using JMP 11.0 (SAS Institute Inc., Cary, NC, USA).
Parametric data were evaluated using one-way analysis of variance (ANOVA) followed by the Tukey-Kramer test. Nonparametric data (hepatic pathological data) were analyzed using the Steel-Dwass test. Differences with p values of less than 0.05 were considered significant. Serum AST and ALT levels in the STAM group were 2.5-to 4-fold higher, respectively, than those in the control group (Iga and Matsuo, 2010) . Therefore, in this study, calorie of d-allose was assumed as 0 kcal.
Results
Effects of
( p < 0.05), indicating that the 3-week HFD successfully induced liver injury. In the DA-STAM group, serum ALT levels were significantly reduced compared with those in the STAM group ( p < 0.05), suggesting that a 2% d-allose-diet for 3 weeks could ameliorate the progression of hepatic inflammation. There were no significant differences in serum TG levels between mice from the control, STAM, and DA-STAM groups. Additionally, no significant difference was found in fasting GLC levels between the STAM and DA-STAM groups, although the fasting GLC levels in both groups were 7-fold higher than those in the control group.
Effects of d-allose on hepatic lipid accumulation in mice
Macroscopic images of liver sections were obtained from each group after the 3-week period with or without a 2% d-allose diet.
The results clearly showed that livers from the STAM group had whitish patches, while those from the DA-STAM and the control groups were reddish in color (data not shown). Microscopic analyses of lipid accumulation in the livers from the three groups were performed using Oil Red O staining ( Fig. 2A, Table 4 ). This analysis revealed that hepatic lipid accumulation in the STAM group (7.78 ± 1.94%) was significantly ( p < 0.01) greater than that in the control group (1.11 ± 0.15%), whereas hepatic lipid accumulation in the DA-STAM group (1.31 ± 0.44%) was completely suppressed compared with that in the STAM group (Table 4 ). In addition, hepatic TG content in the DA-STAM group (10.6 ± 2.0 mg/g liver) was significantly ( p < 0.01) lower than that in the control group (41.6 ± 10.0 mg/g liver; Table 4 ). Hepatic TG content did not differ significantly ( p = 0.27) between the STAM (25.2 ± 8.8 mg/g liver) and DA-STAM (10.6 ± 2.0 mg/g liver) groups. Although hepatic TG content relative to body weight did not differ significantly between groups, that of the STAM group was 1.4-fold higher than that of the control group, while that of the DA-STAM group was 0.4-fold lower than that of the STAM group (Table 4) .
Effects of d-allose on hepatic pathology diagnosis in mice
For semiquantitative diagnostic evaluation of hepatic pathology (Kleiner et al., 2005) , H&E-stained liver sections in the control, STAM, and DA-STAM groups (Fig. 2B) were scored based on the degree of steatosis, lobular inflammation, and hepatocellular ballooning and on the NAS. As shown in Fig. 3A, 3B , and 3D, the steatosis and lobular inflammation scores and NAS in the STAM group were significantly ( p < 0.05) higher than those in the control group. In the DA-STAM group, however, these diagnostic NAFLD/NASH scores were reduced by consumption of a diet containing 2% d-allose for 3 weeks. In particular, the steatosis scores and NAS in the DA-STAM group (0.1 ± 0.1 and 1.6 ± 0.3, respectively) were significantly ( p < 0.05) lower than those in the STAM group (1.2 ± 0.2 and 3.7 ± 0.5, respectively). As shown in Fig. 3D , the percentage of cases diagnosed as NASH, borderline- Values are means ± SEM; n = 5~8; Different superscript letters indicate significant difference ( p < 0.05) between groups in each parameter. AST, aspartate aminotransferase; ALT, alanine aminotransferase; TG, triacylglycerol; GLC, glucose Fig. 4C and 4E ) compared with those in the STAM group. In contrast, there were no significant differences in the expression of Pparα and Lxrα between the DA-STAM and STAM groups (Fig. 4A and 4B) . Finally, the mRNA levels of Chrebp ( p = 0.052) and Tnf-α ( p = 0.076) showed a tendency to be downregulated (0.59-fold and 0.66-fold, respectively; Fig. 4D and 4F).
Discussion
In this study, we demonstrated that dietary d-allose has the potential to attenuate the progressive development of steatosis to NASH in STAM mice by reducing serum ALT levels, hepatic fat accumulation, and inflammation, as confirmed by histological analyses of liver sections.
We successfully generated a NAFLD/NASH model in STAM mice by treating mice with STZ and feeding them a HFD.
Induction of NASH in the STAM group was confirmed by increased serum AST, ALT, and GLC levels, together with lipid accumulation and inflammation in the liver, which is consistent with features of human NASH. Although hepatic lipid accumulation was significantly increased in the STAM group compared to that in the control group, serum and hepatic TG levels did not differ between both groups. Additionally, Pparα mRNA levels were significantly decreased, whereas Srebp-1 mRNAs levels were significantly increased in the STAM group compared with those in the control group. The activities of peroxisome proliferator-activated receptor alpha (PPARα) and sterol regulatory element-binding protein 1 (SREBP-1) are associated with fatty acid oxidation and lipogenesis in the liver, respectively (Larter and Farrell, 2006) . Thus, the STAM group exhibited hepatic lipid Values are mean ± SEM, n = 3~8; Different superscript letters indicate significant difference ( p < 0.01) between groups in each parameter. accumulation, as observed by histological analysis, probably owing to the repression of fatty acid oxidation and increased lipogenesis in the liver. Furthermore, the body weights of mice in the STAM group decreased compared to those in the control group. Saito et al. (2015) reported that hepatic lipid profiles showed lower TG levels in STAM mice than in HFD-fed mice. Hence, differences in hepatic TG levels are attributed to differences in body weight and hepatic lipid profile between the STAM and control groups.
Alternatively, the hepatic TG detected in STAM mice may have been lower due to shedding of hepatic cells. Additionally, hypertriglyceridemia occurs in approximately 20 _ 42% of patients with NAFLD (Hamaguchi et al., 2005) , and thus serum TG levels may not necessarily increase in STAM mice. provide insight into their health benefits (Matsuo et al., 2002; Iga and Matsuo, 2010) . Since d-allose is rapidly excreted in the urine (91.2%) and feces (2.7%) within 24 h (Iga and Matsuo, 2010) , we considered it to be a non-caloric sugar in this study. Because the body weights of mice in the STAM and DA-STAM groups were almost the same in our study, and the intake of a d-psicose (a precursor of d-allose)-containing diet was similar to that of a normal diet in rats , the amount of food intake was assumed to be the same in both the STAM and DA-STAM groups. Furthermore, the amount of d-allose-intake was estimated to be 1.22 _ 1.53 g/kg/day based on the d-psicose-containing dietintake and the HFD32-intake Nishikawa et al., 2007) . In the report by on the acute and subchronic toxicity study of d-allose, no differences were found in serum biochemical parameters of rats fed the normal diet and the 3% d-allose-containing diet, and the LD 50 value of d-allose was determined to be 20.5 g/kg. Thus, the 2% d-allose-containing diet used in this study was considered to be safe.
In STAM mice from the DA-STAM group, diabetes was not alleviated, and high serum GLC levels were not reduced by d-allose in our study, probably due to severe injury to pancreatic β-cells induced by STZ. In contrast, we found that the intake of a 2% d-allose-containing diet for 3 weeks in STAM mice could ameliorate progressive hepatic lipid accumulation, although serum TG levels did not differ from that of STAM mice fed a HFD. In a previous report, dietary consumption of 5% d-psicose by ob/ob mice for 15 weeks reduced the onset of simple steatosis and obesity (Itoh et al., 2015) . A comparison of the in vivo anti-steatosis effect of a 5% d-psicose-containing diet for 15 weeks (Itoh et al., 2015) and that of a 2% d-allose-containing diet for 3 weeks described here showed that d-allose may be more effective in preventing hepatic steatosis or NASH than d -psicose, although the experimental design and animal species used in each study differed.
Dietary 3% d-psicose altered lipid metabolism via changes in
Pparα but not Lxrα and Srebp-1 mRNA levels in the liver of rats . Importantly, the expression of PPARα, liver X receptor alpha (LXRα), SREBP-1, and carbohydrate-responsive element-binding protein (ChREBP) is associated with lipogenesis in the liver; therefore, these proteins may be targets for the prevention and treatment of NAFLD and/or NASH (Larter and Farrell, 2006; Dentin et al., 2006; Ahmed and Byrne, 2007) . We therefore evaluated the effects of d-allose on the expression of these genes in the livers of STAM mice fed a 2% d-allosecontaining diet for 3 weeks. Our findings showed that Srebp-1 and
Chrebp mRNA levels were reduced by d-allose, whereas no changes in Pparα and Lxrα mRNA levels were observed.
Additionally, hepatic TG levels in STAM mice fed a 2% d-allosecontaining diet for 3 weeks decreased 0.4-fold compared to those in STAM mice fed a HFD for 3 weeks. SREBP-1 and ChREBP are major transcriptional regulators of TG synthesis in the liver (Dentin et al., 2006; Ahmed and Byrne, 2007) . Thus, d-allose may reduce TG synthesis via suppression of SREBP-1 and ChREBP. Although other sugars, such as GLC and fructose, are known to induce steatosis via activation of SREBP-1 and ChREBP (Ahmed and Byrne, 2007; Samuel, 2011) , d-allose repressed these targets. Thus, we conclude that structural differences in sugars may have different physiological effects on lipid metabolism in the liver.
d-Allose has been reported to alleviate hepatic I/R injury in rats through reductions in serum AST and ALT levels, hepatic MPO activity, and inflammatory cell infiltration (Hossain et al., 2003) . d-Allose-induced anti-inflammatory activity has also been reported in retinal and cerebral I/R injuries in rodent models (Hirooka et al., 2006; Gao et al., 2013) . In addition, Miyawaki et al. (2012) reported that d-allose attenuates cisplatin-induced toxicity, partly as a result of reduced serum and renal tumor necrosis factor (TNF)-α and monocyte chemoattractant protein (MCP)-1 levels.
The present study also showed that d-allose could reduce hepatic
Mcp-1 mRNA levels in STAM mice after consumption of a HFD for 3 weeks. It has been shown that d-allose intake can result in reduced reactive oxygen species levels in I/R injury (Hirooka et al., 2003; Mizote et al., 2011) and in the mitochondria of Neuro2A (Ishihara et al., 2011) , and in decreased 8-hydroxy-2'deoxyguanosine levels in the hippocampus after ischemia (Liu et al., 2014) . Thus, the anti-inflammatory response to d-allose in the liver may be associated with an anti-oxidant effect in NASH.
However, further experiments are needed to elucidate the mechanisms of the anti-oxidant effect of d-allose in the liver.
In conclusion, in this study, we demonstrated that d-allose attenuated lipid accumulation in the livers of STAM mice via suppression of transcription factors related to lipogenic signaling pathways, such as the SREBP-1 pathway, together with hepatic anti-inflammatory effects resulting from reduced expression levels of MCP-1. The preventive effects of d-allose on the progression of NAFLD/NASH should therefore be evaluated as a new physiological role of rare sugars without concerns associated with the risks of common sugars in NAFLD/NASH, although the mechanism needs to be further elucidated.
